Not to my knowledge.
I know for the ISAP study, initiated late last year, conducted by Oxford University and sponsored by Novo Nordisk looking at cognition and the Impact of Semaglutide in Amyloid Positivity ( pre dementia), they went with a suite of Cambridge Cognition products including their voice products. Novo has other links to Cambridge Cognition so there may be some sort of preferred realtionship. However, I would certainly expect us to pick up work from Lilly as they move Tirzepatide in the same direction.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.015(0.84%) |
Mkt cap ! $308.9M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.84 | $1.78 | $252.4K | 138.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2792 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 6891 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |